Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SmofKabiven E in Metastatic NSCLC
NCT03355079Phase 4Terminated
- Sponsor
- Fresenius Kabi
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
A Phase 4 trial of SmofKabiven Peripheral in cancer-related malnutrition (CRM), sponsored by Fresenius Kabi. Started Feb 2018; status: terminated.
02
Drugs
SmofKabiven Peripheral
03
Conditions
cancer-related malnutrition (CRM)
Beyond the preview
Go deeper on NCT03355079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355079.